BB Biotech AG : Operating newsflow and M&A activity as catalysts in Q4
>A challenging Q3, 9M 2020 still in positive terrain - BB Biotech published its Q3 2020 results this morning. The holding company's share price lost 4.3% in € and 3.4% in CHF over the quarter. The portfolio's NAV fell by 10.9% in CHF, 12.1% in € and 8.3% in $, underperforming its benchmark, the Nasdaq Biotechnology Index (NBI), which fell by just -0.8% over the period. The result was a net loss of -CHF 395m (vs -CHF 382m in Q3 2019). Nevertheless, the holding c...Co.'s principal activity is to invest in biotechnology companies globally. The investments are held through its wholly-owned subsidiaries: Biotech Focus N.V., Biotech Invest N.V., Biotech Target N.V., and Biotech Growth N.V., all of which are located in Curacao. Co. acquires holdings in companies in the biotechnology growth market. The focus of the holdings is on quoted companies that are concentrating on the development and marketing of innovative medicines. For the selection of holdings, Co. relies on fundamental analysis by physicians and molecular biologists.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.